SG185724A1 - Method for preparing an enriched igg composition from plasma - Google Patents
Method for preparing an enriched igg composition from plasma Download PDFInfo
- Publication number
- SG185724A1 SG185724A1 SG2012086245A SG2012086245A SG185724A1 SG 185724 A1 SG185724 A1 SG 185724A1 SG 2012086245 A SG2012086245 A SG 2012086245A SG 2012086245 A SG2012086245 A SG 2012086245A SG 185724 A1 SG185724 A1 SG 185724A1
- Authority
- SG
- Singapore
- Prior art keywords
- igg
- solution
- composition
- precipitate
- fraction
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 261
- 239000000203 mixture Substances 0.000 title claims abstract description 205
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 40
- 238000000746 purification Methods 0.000 claims abstract description 23
- 238000001990 intravenous administration Methods 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 388
- 239000000243 solution Substances 0.000 claims description 209
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 180
- 238000001556 precipitation Methods 0.000 claims description 180
- 239000002244 precipitate Substances 0.000 claims description 133
- 239000000725 suspension Substances 0.000 claims description 128
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 125
- 108090000623 proteins and genes Proteins 0.000 claims description 96
- 102000004169 proteins and genes Human genes 0.000 claims description 95
- 239000000872 buffer Substances 0.000 claims description 83
- 239000000706 filtrate Substances 0.000 claims description 73
- 238000001914 filtration Methods 0.000 claims description 72
- 229960000583 acetic acid Drugs 0.000 claims description 70
- 238000005507 spraying Methods 0.000 claims description 60
- 108010049003 Fibrinogen Proteins 0.000 claims description 48
- 102000008946 Fibrinogen Human genes 0.000 claims description 48
- 229940012952 fibrinogen Drugs 0.000 claims description 48
- 230000001376 precipitating effect Effects 0.000 claims description 48
- 239000006228 supernatant Substances 0.000 claims description 46
- 238000000108 ultra-filtration Methods 0.000 claims description 42
- 239000003599 detergent Substances 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 34
- 239000007921 spray Substances 0.000 claims description 31
- 239000012362 glacial acetic acid Substances 0.000 claims description 30
- 239000012528 membrane Substances 0.000 claims description 27
- 238000011026 diafiltration Methods 0.000 claims description 20
- 239000000377 silicon dioxide Substances 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 20
- 235000012239 silicon dioxide Nutrition 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
- 238000005119 centrifugation Methods 0.000 claims description 16
- 238000004255 ion exchange chromatography Methods 0.000 claims description 15
- 229910019142 PO4 Inorganic materials 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 239000010452 phosphate Substances 0.000 claims description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 238000005277 cation exchange chromatography Methods 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 238000001728 nano-filtration Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- 239000004471 Glycine Substances 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 10
- 239000011148 porous material Substances 0.000 claims description 10
- 239000012538 diafiltration buffer Substances 0.000 claims description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 7
- 229940068968 polysorbate 80 Drugs 0.000 claims description 7
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 6
- 239000005909 Kieselgur Substances 0.000 claims description 6
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 230000007813 immunodeficiency Effects 0.000 claims description 5
- 238000005349 anion exchange Methods 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 102000006395 Globulins Human genes 0.000 claims description 3
- 108010044091 Globulins Proteins 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 1
- 238000011097 chromatography purification Methods 0.000 claims 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 claims 1
- 229920002113 octoxynol Polymers 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 48
- 230000002829 reductive effect Effects 0.000 abstract description 32
- 201000010099 disease Diseases 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 238000007920 subcutaneous administration Methods 0.000 abstract description 10
- 238000007918 intramuscular administration Methods 0.000 abstract description 9
- 229940027941 immunoglobulin g Drugs 0.000 description 388
- 235000019441 ethanol Nutrition 0.000 description 214
- 230000006872 improvement Effects 0.000 description 98
- 235000018102 proteins Nutrition 0.000 description 86
- 238000011282 treatment Methods 0.000 description 69
- 238000000605 extraction Methods 0.000 description 67
- 229910002012 Aerosil® Inorganic materials 0.000 description 46
- 238000011534 incubation Methods 0.000 description 42
- 238000005194 fractionation Methods 0.000 description 40
- 230000008569 process Effects 0.000 description 37
- 238000004090 dissolution Methods 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 36
- 230000003024 amidolytic effect Effects 0.000 description 34
- 108060003951 Immunoglobulin Proteins 0.000 description 28
- 102000018358 immunoglobulin Human genes 0.000 description 28
- 238000005352 clarification Methods 0.000 description 27
- 239000011536 extraction buffer Substances 0.000 description 26
- 238000009472 formulation Methods 0.000 description 25
- 239000012535 impurity Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 23
- 238000010979 pH adjustment Methods 0.000 description 22
- 238000011084 recovery Methods 0.000 description 22
- 239000012065 filter cake Substances 0.000 description 21
- 239000003795 chemical substances by application Substances 0.000 description 20
- 229910021485 fumed silica Inorganic materials 0.000 description 19
- -1 carboxylate anions Chemical class 0.000 description 18
- 229940099472 immunoglobulin a Drugs 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 12
- 239000000356 contaminant Substances 0.000 description 12
- 235000021317 phosphate Nutrition 0.000 description 12
- 229940072221 immunoglobulins Drugs 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 239000011534 wash buffer Substances 0.000 description 11
- 229910002019 Aerosil® 380 Inorganic materials 0.000 description 10
- 238000005571 anion exchange chromatography Methods 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000006172 buffering agent Substances 0.000 description 9
- 229940009600 gammagard Drugs 0.000 description 9
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 102000004338 Transferrin Human genes 0.000 description 8
- 108090000901 Transferrin Proteins 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 8
- 235000019799 monosodium phosphate Nutrition 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000012581 transferrin Substances 0.000 description 8
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 description 7
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 7
- 201000006417 multiple sclerosis Diseases 0.000 description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000012134 supernatant fraction Substances 0.000 description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 6
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 6
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 description 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 6
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010000234 Abortion spontaneous Diseases 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 208000000995 spontaneous abortion Diseases 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 239000008364 bulk solution Substances 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000003595 mist Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000011800 void material Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000008190 Agammaglobulinemia Diseases 0.000 description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 3
- 208000028399 Critical Illness Diseases 0.000 description 3
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 3
- 208000007985 Erythema Infectiosum Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 208000011200 Kawasaki disease Diseases 0.000 description 3
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 208000009567 Neonatal Alloimmune Thrombocytopenia Diseases 0.000 description 3
- 206010053854 Opsoclonus myoclonus Diseases 0.000 description 3
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 3
- 241000721454 Pemphigus Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000031951 Primary immunodeficiency Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 3
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 3
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 3
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 3
- 208000003441 Transfusion reaction Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 238000011178 cuno filtration Methods 0.000 description 3
- 238000011118 depth filtration Methods 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 201000008319 inclusion body myositis Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 3
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 3
- 201000006938 muscular dystrophy Diseases 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 3
- 229960002446 octanoic acid Drugs 0.000 description 3
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 3
- 238000011020 pilot scale process Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 230000006920 protein precipitation Effects 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- YFSUTJLHUFNCNZ-UHFFFAOYSA-M 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YFSUTJLHUFNCNZ-UHFFFAOYSA-M 0.000 description 2
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000003352 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 2
- 108090000113 Plasma Kallikrein Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- WOQQAWHSKSSAGF-WXFJLFHKSA-N decyl beta-D-maltopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOQQAWHSKSSAGF-WXFJLFHKSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 206010066130 hyper-IgM syndrome Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000013621 viresolve pro solution Substances 0.000 description 2
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- SNGREZUHAYWORS-UHFFFAOYSA-M 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoate Chemical compound [O-]C(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F SNGREZUHAYWORS-UHFFFAOYSA-M 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010032597 Cohn fraction II Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 101000837639 Homo sapiens Thyroxine-binding globulin Proteins 0.000 description 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101150114843 Mgll gene Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010057863 Selective IgG subclass deficiency Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102100028709 Thyroxine-binding globulin Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- PNZVFASWDSMJER-UHFFFAOYSA-N acetic acid;lead Chemical compound [Pb].CC(O)=O PNZVFASWDSMJER-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 101150039352 can gene Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004690 coupled electron pair approximation Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012471 diafiltration solution Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- XJFQCYIFOWHHFN-PLKCGDGVSA-N hypertensinogen Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 XJFQCYIFOWHHFN-PLKCGDGVSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- SNGREZUHAYWORS-UHFFFAOYSA-N perfluorooctanoic acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F SNGREZUHAYWORS-UHFFFAOYSA-N 0.000 description 1
- 108010055837 phosphocarrier protein HPr Proteins 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013579 wash concentrate Substances 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
- B01D15/424—Elution mode
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010202125A AU2010202125B1 (en) | 2010-05-26 | 2010-05-26 | A method to produce an immunoglobulin preparation with improved yield |
| PCT/US2010/036470 WO2011149472A1 (en) | 2010-05-26 | 2010-05-27 | Method for preparing an enriched igg composition from plasma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG185724A1 true SG185724A1 (en) | 2013-01-30 |
Family
ID=42727304
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012086245A SG185724A1 (en) | 2010-05-26 | 2010-05-27 | Method for preparing an enriched igg composition from plasma |
| SG10201505161SA SG10201505161SA (en) | 2010-05-26 | 2010-05-27 | Method For Preparing An Enriched IGG Composition From Plasma |
| SG2012086252A SG185725A1 (en) | 2010-05-26 | 2011-05-26 | Removal of serine proteases by treatment with finely divided silicon dioxide |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201505161SA SG10201505161SA (en) | 2010-05-26 | 2010-05-27 | Method For Preparing An Enriched IGG Composition From Plasma |
| SG2012086252A SG185725A1 (en) | 2010-05-26 | 2011-05-26 | Removal of serine proteases by treatment with finely divided silicon dioxide |
Country Status (25)
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI532498B (zh) | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| DK2477603T3 (en) * | 2009-09-17 | 2016-06-13 | Baxalta Inc | STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| US8772462B2 (en) | 2010-05-26 | 2014-07-08 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| CN103119058A (zh) * | 2010-07-23 | 2013-05-22 | 巴克斯特国际公司 | 由血浆生产间-α-抑制蛋白(IAIP) |
| HUE029232T2 (en) * | 2011-04-08 | 2017-02-28 | Univ Costa Rica | A method for preparing injectable formulations of protein derived from blood, and materials obtained using said method |
| HUE038441T2 (hu) | 2011-12-13 | 2018-10-29 | Baxalta GmbH | Autoantitestek mérése alacsony vezetõképességû körülmények között |
| TWI629283B (zh) | 2012-02-23 | 2018-07-11 | 巴克斯歐塔公司 | 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱 |
| RU2487725C1 (ru) * | 2012-03-15 | 2013-07-20 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации (ФГУП "НПО "Микроген" Минздрава России) | Способ получения концентрированного иммуноглобулинового препарата для подкожного введения |
| CN103197053B (zh) * | 2013-03-15 | 2015-02-18 | 上海市血液中心 | 一种抗IgA抗体检测试剂盒 |
| AU2013203043B2 (en) * | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
| CN104072601A (zh) * | 2014-07-03 | 2014-10-01 | 成都蓉生药业有限责任公司 | 血液制品中fii沉淀的制备方法 |
| CN104086642A (zh) * | 2014-07-03 | 2014-10-08 | 成都蓉生药业有限责任公司 | 血液制品中fi+iii上清的制备方法 |
| CN104086646B (zh) * | 2014-07-03 | 2018-10-09 | 成都蓉生药业有限责任公司 | 血液制品中fv沉淀的制备方法 |
| GB201413227D0 (en) * | 2014-07-25 | 2014-09-10 | Bioproducts Lab Ltd | Process |
| US20170313767A1 (en) | 2014-10-21 | 2017-11-02 | The General Hospital Corporation | Methods of diagnosis and treatment of tuberculosis and infection |
| CN204424090U (zh) | 2014-11-28 | 2015-06-24 | 比亚迪股份有限公司 | 薄膜电容器 |
| CN107921080A (zh) * | 2015-04-02 | 2018-04-17 | K·黄 | 由组分iii制造并纯化出用于静脉注射的凝血酶原复合物浓缩剂的方法以及治疗和预防具有抑制剂的a型血友病或感染了hiv‑1和hiv‑2的b型血友病患者的方法 |
| WO2016161421A1 (en) * | 2015-04-02 | 2016-10-06 | Kieu Hoang | A method of manufacturing intravenous immunoglobulin from fraction iii |
| WO2016161423A1 (en) * | 2015-04-02 | 2016-10-06 | Kieu Hoang | Process of cloning and further purification to make a recombinant intravenous immunoglobulin |
| WO2017058879A1 (en) * | 2015-09-29 | 2017-04-06 | Kieu Hoang | A method of manufacturing intravenous immunoglobulin from fraction iii |
| WO2017062536A2 (en) * | 2015-10-06 | 2017-04-13 | Kieu Hoang | A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv |
| CN106800583A (zh) * | 2015-11-26 | 2017-06-06 | 上海洲跃生物科技有限公司 | 一种速溶无析出的冻干人纤维蛋白原制备工艺 |
| EP3275897A1 (en) * | 2016-07-27 | 2018-01-31 | Biotest AG | Process for preparing immunoglobulin compositions |
| WO2018050873A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| US11166915B2 (en) | 2016-09-16 | 2021-11-09 | Leukocare Ag | Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| AU2017328632A1 (en) * | 2016-09-16 | 2019-04-04 | Leukocare Ag | A novel method for stabilization of a biopharmaceutical drug product during processing |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| AU2018253931A1 (en) * | 2017-04-21 | 2019-11-21 | Csl Behring Ag | Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| KR20200100771A (ko) * | 2017-12-19 | 2020-08-26 | 체에스엘 베링 렝나우 아게 | 알킬 글리코시드에 의한 단백질 정제 및 바이러스 불활성화 |
| EP3774894A1 (en) * | 2018-04-12 | 2021-02-17 | Amgen Inc. | Methods for making stable protein compositions |
| CN108733099B (zh) * | 2018-05-31 | 2020-08-11 | 上海药明生物技术有限公司 | 低pH孵育和中和的自动调节系统及方法 |
| JP2022551566A (ja) * | 2019-10-11 | 2022-12-12 | 武田薬品工業株式会社 | 第ＸＩａ因子のヘパリン非感受性アッセイ |
| CN114667151B (zh) * | 2019-11-04 | 2025-05-23 | 万能溶剂有限公司 | 用于肌肉再生的血浆级分 |
| US20230002444A1 (en) * | 2019-11-20 | 2023-01-05 | Csl Behring Ag | Method for extracting a protein from a precipitate and method for precipitating impurities |
| MX2022011950A (es) * | 2020-03-31 | 2022-10-21 | Takeda Pharmaceuticals Co | Metodo para producir una preparacion de inmunoglobulina a partir de plasma con reduccion del inhibidor de c-1. |
| US11732004B2 (en) | 2020-04-10 | 2023-08-22 | Plasma Technologies, Llc | Compositions and methods for simplified high efficiency isolation of proteins |
| CN111961130B (zh) * | 2020-08-31 | 2021-09-10 | 华兰生物工程重庆有限公司 | 一种从血浆中提取并分离IgM和IgG的方法 |
| BR112023003010A2 (pt) * | 2020-10-01 | 2023-04-04 | Takeda Pharmaceuticals Co | Método de fracionamento de plasma humano, composição, e, preparações de um fator de coagulação, de igg, de um membro selecionado de a1pi, at-iii e uma combinação dos mesmos e de albumina |
| JP2024501025A (ja) | 2020-12-28 | 2024-01-10 | プラズマ テクノロジーズ エルエルシー | 免疫グロブリンｇのプロセススケールでの単離のためのシステム及び方法 |
| CN112574296B (zh) * | 2020-12-30 | 2023-05-19 | 中国医学科学院输血研究所 | 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法 |
| AU2022317368A1 (en) | 2021-07-29 | 2024-02-22 | Csl Behring Ag | Method of purifying immunoglobulin g and uses thereof |
| CN118434753A (zh) | 2021-10-27 | 2024-08-02 | 等离子技术有限责任公司 | 用于分离蛋白质的组合物和方法 |
| KR102779378B1 (ko) * | 2022-01-05 | 2025-03-12 | 한양대학교 에리카산학협력단 | 1-알릴이소크로만 유도체와 이의 제조방법 |
| KR20230121373A (ko) * | 2022-02-11 | 2023-08-18 | 주식회사 녹십자 | 인자 xiii의 정제방법 |
| WO2023170553A1 (en) | 2022-03-07 | 2023-09-14 | Takeda Pharmaceutical Company Limited | Affinity chromatographic production of clinical human igg products |
| CA3244889A1 (en) | 2022-03-08 | 2023-09-14 | Equashield Medical Ltd | FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM |
| KR20250004876A (ko) | 2022-05-02 | 2025-01-08 | 다케다 야쿠힌 고교 가부시키가이샤 | 한외여과를 통한 혈장으로부터 콘 풀 농축액을 제조하는 방법 |
| CA3249460A1 (en) | 2022-06-22 | 2023-12-28 | Ageronix SA | ALPHA1-ANTITRYPSIN FOR USE IN THE TREATMENT OF DISEASES OR DISORDERS OF THE NERVOUS SYSTEM SUCH AS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY |
| AU2024247735A1 (en) | 2023-03-29 | 2025-10-30 | Csl Behring Ag | Methods of identifying immunoglobulin associated with adverse reactions |
| WO2025008781A1 (en) | 2023-07-04 | 2025-01-09 | Csl Behring Ag | Method of purification |
| WO2025068923A2 (en) | 2023-09-26 | 2025-04-03 | Takeda Pharmaceutical Company Limited | IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA |
| WO2025085544A1 (en) * | 2023-10-17 | 2025-04-24 | Plasma Technologies, Llc | Integrated process for isolation of plasma proteins |
| PL448469A1 (pl) * | 2024-04-30 | 2025-11-03 | Deveris Polska Spółka Z Ograniczoną Odpowiedzialnością | Przedmiotem wynalazku jest sposób wzbogacania preparatów plazmy krwi drobiowej w immunoglobulinę G (IgG) |
| WO2025229607A1 (en) | 2024-05-03 | 2025-11-06 | Csl Behring Ag | Systems and methods for solid-liquid separation |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390074A (en) * | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
| SE348942B (cg-RX-API-DMAC7.html) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| US4056614A (en) | 1972-09-22 | 1977-11-01 | Marc Bonneau | Immunity depressant medicine |
| US3998946A (en) * | 1975-04-23 | 1976-12-21 | The Regents Of The University Of Minnesota | Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same |
| DE2801123C2 (de) * | 1977-01-26 | 1986-01-02 | Armour Pharma GmbH & Co KG, 3440 Eschwege | Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates |
| US4296027A (en) | 1977-08-31 | 1981-10-20 | The Regents Of The University Of Minnesota | Pure intravenous human and animal gamma globulins |
| US4136094A (en) | 1977-08-31 | 1979-01-23 | The Regents Of The University Of Minnesota | Preparation of intravenous human and animal gamma globulins and isolation of albumin |
| US4550019A (en) * | 1978-03-22 | 1985-10-29 | South Africa Inventions Development Corporation | Manufacture and use of fowl egg antibodies |
| US4357272A (en) * | 1978-03-22 | 1982-11-02 | The South African Inventions Development Corporation | Recovering purified antibodies from egg yolk |
| DE2901822A1 (de) * | 1979-01-18 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt |
| DE2902158A1 (de) | 1979-01-20 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen |
| US4228154A (en) | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
| US4378346A (en) * | 1979-08-15 | 1983-03-29 | Tankersley Donald L | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production |
| US4499073A (en) * | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
| JPS5855432A (ja) | 1981-09-29 | 1983-04-01 | Fujirebio Inc | 静脈注射用免疫グロブリンの製法 |
| US4439358A (en) | 1982-06-17 | 1984-03-27 | Miles Laboratories, Inc. | Method of preparing alpha-1-proteinase inhibitor |
| US4624780A (en) | 1982-06-28 | 1986-11-25 | Alpha Therapeutic Corporation | Fractionation of blood plasma |
| DE3247150A1 (de) | 1982-12-21 | 1984-06-28 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems |
| DK166763B1 (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
| US5061237A (en) | 1985-07-02 | 1991-10-29 | Cytomed Medizintechnik Gmbh | Method of purifying whole blood |
| DE3523615A1 (de) | 1985-07-02 | 1987-01-15 | Cytomed Medizintechnik | Medizinisches geraet, insbesondere kanuele, katheter oder implantat |
| JPH0742235B2 (ja) | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
| US5136094A (en) | 1988-03-10 | 1992-08-04 | Air Products And Chemicals, Inc. | Process for the synthesis of secondary formamides |
| US5055447A (en) | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
| JP2871709B2 (ja) | 1988-11-21 | 1999-03-17 | 住友製薬株式会社 | 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法 |
| US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
| EP0440509A3 (en) * | 1990-02-02 | 1991-12-18 | Common Services Agency | Novel cell growth medium components and process for producing same |
| ES2074490T5 (es) * | 1990-03-22 | 2004-02-16 | Biotest Pharma Gmbh | Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa. |
| US5130451A (en) * | 1991-03-28 | 1992-07-14 | Amoco Corporation | Process for preparing carboxyaryl phosphates |
| US5324425A (en) * | 1992-08-26 | 1994-06-28 | Ellison Billy L | Method and apparatus for removing solids from aqueous wash solutions |
| FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
| FR2711371B1 (fr) | 1993-10-18 | 1995-12-29 | Aetsrn | Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu. |
| US5610285A (en) | 1994-08-24 | 1997-03-11 | Bayer Corporation | Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| AUPN858596A0 (en) * | 1996-03-08 | 1996-04-04 | Csl Limited | Filtration of plasma precipitates using cellulose filter aid |
| TW491855B (en) * | 1996-08-07 | 2002-06-21 | Csl Ltd | Purification of immunoglobulins |
| US5783640A (en) * | 1997-03-04 | 1998-07-21 | The Goodyear Tire & Rubber Company | Rubber compositions containing a disodium salt of 2, 2'-dithiosalicyclic acid |
| CA2232420A1 (en) | 1997-03-19 | 1998-09-19 | The Green Cross Corporation | Immunoglobulin preparation and preparation process thereof |
| GB9705810D0 (en) | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
| AT407114B (de) | 1997-06-10 | 2000-12-27 | Immuno Ag | Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung |
| US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| CN1149100C (zh) | 1997-10-23 | 2004-05-12 | 三菱制药株式会社 | 可室温贮存的免疫球蛋白静脉注射制剂 |
| US20020114802A1 (en) | 1998-02-10 | 2002-08-22 | Tjellstrom Bo Arthur Einar | Oral immunoglobulin treatment for inflammatory bowel disease |
| AT406873B (de) | 1998-02-25 | 2000-10-25 | Immuno Ag | Verfahren zur abreicherung von pathogenen aus proteinhaltigen lösungen |
| DE19932782A1 (de) * | 1999-07-14 | 2001-01-18 | Biotest Pharma Gmbh | Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung |
| DE60018777T2 (de) | 1999-10-21 | 2006-02-02 | Alcon Inc. | Medikamentenversorgung der sub-tenon |
| DE10008519C1 (de) | 2000-02-21 | 2001-07-12 | Dica Technologies Ag | Verfahren und Kommunikationseinrichtungen zum Aufbau von gesicherten E-Mail-Verkehr zwischen Mail-Domains des Internet |
| DE10008619A1 (de) * | 2000-02-24 | 2001-09-06 | Immuno Vet As Lynge | Mikroorganismenfreies IgG-Präparat, Verfahren zu seiner Herstellung und seine Verwendung in der Tieraufzucht und in der Tiermast |
| SE0001128D0 (sv) | 2000-03-30 | 2000-03-30 | Amersham Pharm Biotech Ab | A method of producing IgG |
| US20020098182A1 (en) | 2000-09-28 | 2002-07-25 | Richard Weisbart | Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G |
| WO2002030983A2 (de) | 2000-10-13 | 2002-04-18 | Octapharma Ag | Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung |
| FR2824568B1 (fr) | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
| EP1463527A4 (en) | 2001-10-04 | 2005-05-11 | Protein Therapeutics Inc | USE OF GAMMAGLOBULIN FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES |
| US6893639B2 (en) | 2001-10-19 | 2005-05-17 | Hemacare Corporation | Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates |
| US7777006B2 (en) * | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| DE602004025100D1 (de) * | 2003-05-23 | 2010-03-04 | Novo Nordisk Healthcare Ag | Stabilisierung von proteinen in lösung |
| WO2005012354A1 (en) | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
| US20050054003A1 (en) | 2003-09-10 | 2005-03-10 | Stenland Christopher J. | Prion clearance using particulate metal oxides |
| WO2005046587A2 (en) | 2003-11-08 | 2005-05-26 | Prothera Biologics | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| JP2008500959A (ja) | 2004-01-30 | 2008-01-17 | スオメン プナイネン リスティ ヴェリパルヴェル | ウイルスについて安全な免疫グロブリンの製造方法 |
| EP1718675B2 (en) | 2004-02-27 | 2017-01-25 | Octapharma AG | A method of providing a purified, virus safe antibody preparation |
| NZ608860A (en) | 2005-02-14 | 2014-10-31 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| US8715649B2 (en) | 2005-06-07 | 2014-05-06 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity |
| WO2009005877A2 (en) * | 2007-04-20 | 2009-01-08 | Regents Of The University Of Colorado | Alpha-i antitrypsin having no significant serine protease inhibitor activity |
| US7807435B2 (en) | 2005-08-11 | 2010-10-05 | Baxter International Inc. | Method for the purification of alpha-1 proteinase inhibitor (a1PI) |
| CA2627264A1 (en) | 2005-09-19 | 2007-04-12 | Csl Behring Gmbh | Factor h for the treatment of chronic nephropathies and production thereof |
| FR2894145B1 (fr) | 2005-12-07 | 2008-10-17 | Lab Francais Du Fractionnement | Utilisation de facteur h du complement a titre de medicament |
| CA2640010A1 (en) * | 2006-01-25 | 2007-08-02 | Octapharma Ag | Purification and use of a factor for supporting wound healing |
| US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| EP1852443A1 (en) * | 2006-05-05 | 2007-11-07 | Leukocare AG | Biocompatible three dimensional matrix for the immobilization of biological substances |
| DE102007001521A1 (de) * | 2007-01-10 | 2008-07-17 | Matthias, Torsten, Dr. | Verwendung von Cohn-Oncley-Fraktionen II und II/III zur Behandlung des systemischen Lupus erythematodes |
| ES2595059T3 (es) * | 2007-03-20 | 2016-12-27 | Csl Behring Gmbh | Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano |
| DE202007004346U1 (de) | 2007-03-21 | 2007-10-31 | Rehau Ag + Co | Rohranordnung |
| KR20100019999A (ko) | 2007-06-13 | 2010-02-19 | 체에스엘 베링 게엠베하 | 출혈 장애의 치료법 및 예방 처치에 있어서의 혈관외 투여용 ｖｗｆ 안정화된 ｆｖｉｉｉ 제제 및 ｆｖｉｉｉ 무함유 ｖｗｆ 제제의 용도 |
| CA2695972A1 (en) | 2007-08-13 | 2009-02-19 | Baxter Healthcare S.A. | Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease |
| CA2696417A1 (en) * | 2007-10-02 | 2009-04-09 | Csl Limited | Therapeutic antibody purification method and method of use |
| SG10201608059VA (en) | 2007-12-28 | 2016-11-29 | Baxter Int | Recombinant vwf formulations |
| CN101249265B (zh) * | 2008-04-11 | 2010-10-27 | 三九集团湛江开发区双林药业有限公司 | 静脉注射用人乙肝免疫球蛋白及其制备方法 |
| EP2291654B1 (en) | 2008-05-28 | 2018-04-11 | Prothera Biologics, Inc. | Preparation and composition of inter-alpha inhibitor proteins from blood |
| CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
| CN201169579Y (zh) * | 2008-06-30 | 2008-12-24 | 山东泰邦生物制品有限公司 | 一种人血白蛋白分离用乙醇雾化扩散装置 |
| TWI670072B (zh) | 2008-10-21 | 2019-09-01 | 美商巴克斯歐塔公司 | 凍乾的重組ｖｗｆ調配物 |
| CA2742994A1 (en) | 2008-11-12 | 2010-05-20 | Baxter International Inc. | Purification of butyrylcholinesterase using membrane adsorption |
| US8546548B2 (en) | 2009-05-27 | 2013-10-01 | Baxter International Inc. | Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
| AT514675B1 (de) | 2009-07-23 | 2019-05-15 | Baxalta Inc | Herstellung von faktor h (fh) und fh-derivaten aus plasma |
| US8772462B2 (en) * | 2010-05-26 | 2014-07-08 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| EA202090067A3 (ru) | 2010-07-08 | 2020-07-31 | Баксалта Инкорпорейтид | Способ получения рекомбинантного adamts13 в культуре клеток |
| CN103119058A (zh) * | 2010-07-23 | 2013-05-22 | 巴克斯特国际公司 | 由血浆生产间-α-抑制蛋白(IAIP) |
-
2010
- 2010-05-26 AU AU2010202125A patent/AU2010202125B1/en active Active
- 2010-05-27 EP EP14176511.5A patent/EP2803349B1/en active Active
- 2010-05-27 CN CN201510158213.1A patent/CN104958761B/zh active Active
- 2010-05-27 PL PL12190138T patent/PL2554160T3/pl unknown
- 2010-05-27 PL PL10727539T patent/PL2445482T3/pl unknown
- 2010-05-27 EP EP10727539.8A patent/EP2445482B1/en active Active
- 2010-05-27 SG SG2012086245A patent/SG185724A1/en unknown
- 2010-05-27 PT PT121901383T patent/PT2554160E/pt unknown
- 2010-05-27 MX MX2012013682A patent/MX349815B/es active IP Right Grant
- 2010-05-27 EA EA201500848A patent/EA034602B1/ru not_active IP Right Cessation
- 2010-05-27 KR KR1020127033758A patent/KR101593265B1/ko active Active
- 2010-05-27 MY MYPI2012005077A patent/MY160551A/en unknown
- 2010-05-27 EA EA201291355A patent/EA023446B1/ru not_active IP Right Cessation
- 2010-05-27 ES ES12190138.3T patent/ES2536093T3/es active Active
- 2010-05-27 ES ES14176511T patent/ES2959234T3/es active Active
- 2010-05-27 DK DK10727539.8T patent/DK2445482T3/da active
- 2010-05-27 WO PCT/US2010/036470 patent/WO2011149472A1/en not_active Ceased
- 2010-05-27 CN CN201080067929.6A patent/CN102970975B/zh active Active
- 2010-05-27 PT PT107275398T patent/PT2445482E/pt unknown
- 2010-05-27 KR KR1020167002347A patent/KR101647617B1/ko active Active
- 2010-05-27 BR BR112012029893-3A patent/BR112012029893B1/pt active IP Right Grant
- 2010-05-27 HR HRP20141109AT patent/HRP20141109T1/hr unknown
- 2010-05-27 AR ARP100101844A patent/AR076800A1/es active IP Right Grant
- 2010-05-27 JP JP2013512585A patent/JP5876474B2/ja active Active
- 2010-05-27 MX MX2014006981A patent/MX364252B/es unknown
- 2010-05-27 MY MYPI2015002952A patent/MY173299A/en unknown
- 2010-05-27 CA CA2800155A patent/CA2800155A1/en not_active Abandoned
- 2010-05-27 HU HUE14176511A patent/HUE064400T2/hu unknown
- 2010-05-27 ES ES10727539.8T patent/ES2525492T3/es active Active
- 2010-05-27 SG SG10201505161SA patent/SG10201505161SA/en unknown
- 2010-05-27 PL PL14176511.5T patent/PL2803349T3/pl unknown
- 2010-05-27 DK DK12190138T patent/DK2554160T3/da active
- 2010-05-27 EP EP12190138.3A patent/EP2554160B1/en active Active
- 2010-05-27 TW TW099117123A patent/TWI531577B/zh active
- 2010-05-27 US US12/789,365 patent/US8993734B2/en active Active
- 2010-09-29 AU AU2010224461A patent/AU2010224461B2/en active Active
-
2011
- 2011-05-26 TW TW100118581A patent/TWI504607B/zh active
- 2011-05-26 MY MYPI2012005078A patent/MY161617A/en unknown
- 2011-05-26 CN CN201180036374.3A patent/CN103068365B/zh active Active
- 2011-05-26 CN CN201810967589.0A patent/CN109180776B/zh active Active
- 2011-05-26 DK DK11729200.3T patent/DK2575762T3/da active
- 2011-05-26 KR KR1020127033759A patent/KR101716534B1/ko active Active
- 2011-05-26 CA CA2800272A patent/CA2800272A1/en not_active Abandoned
- 2011-05-26 HR HRP20140944AT patent/HRP20140944T1/hr unknown
- 2011-05-26 BR BR112012029897A patent/BR112012029897A2/pt not_active Application Discontinuation
- 2011-05-26 MX MX2012013689A patent/MX337028B/es active IP Right Grant
- 2011-05-26 AU AU2011258111A patent/AU2011258111B2/en active Active
- 2011-05-26 EP EP11729200.3A patent/EP2575762B1/en not_active Revoked
- 2011-05-26 AR ARP110101811A patent/AR082093A1/es active IP Right Grant
- 2011-05-26 EA EA201691558A patent/EA034530B1/ru not_active IP Right Cessation
- 2011-05-26 PT PT117292003T patent/PT2575762E/pt unknown
- 2011-05-26 EP EP22164436.2A patent/EP4039249A1/en active Pending
- 2011-05-26 JP JP2013512262A patent/JP5866345B2/ja active Active
- 2011-05-26 PL PL11729200T patent/PL2575762T3/pl unknown
- 2011-05-26 TW TW104127086A patent/TWI543989B/zh active
- 2011-05-26 CN CN201510171065.7A patent/CN104840946A/zh active Pending
- 2011-05-26 EA EA201291367A patent/EA025826B1/ru not_active IP Right Cessation
- 2011-05-26 ES ES11729200.3T patent/ES2505465T3/es active Active
- 2011-05-26 EP EP20140166189 patent/EP2796128A1/en active Pending
- 2011-05-26 SG SG2012086252A patent/SG185725A1/en unknown
-
2012
- 2012-10-16 US US13/653,332 patent/US8940877B2/en active Active
- 2012-11-20 IL IL223150A patent/IL223150A0/en unknown
- 2012-11-20 IL IL223149A patent/IL223149A/en active IP Right Grant
- 2012-11-23 CL CL2012003291A patent/CL2012003291A1/es unknown
- 2012-11-23 CL CL2012003290A patent/CL2012003290A1/es unknown
- 2012-11-23 CO CO12212759A patent/CO6660439A2/es unknown
- 2012-11-23 CO CO12212751A patent/CO6660438A2/es unknown
- 2012-11-26 MX MX2019004482A patent/MX2019004482A/es unknown
-
2014
- 2014-06-19 US US14/309,668 patent/US20150133644A1/en not_active Abandoned
- 2014-12-17 CL CL2014003430A patent/CL2014003430A1/es unknown
-
2015
- 2015-05-04 HR HRP20150484TT patent/HRP20150484T1/hr unknown
- 2015-08-14 JP JP2015160018A patent/JP2016053016A/ja active Pending
-
2016
- 2016-01-04 JP JP2016000025A patent/JP2016155798A/ja active Pending
- 2016-02-18 HK HK16101817.1A patent/HK1213790A1/zh unknown
- 2016-05-09 AU AU2016202973A patent/AU2016202973B2/en active Active
- 2016-10-27 JP JP2016210160A patent/JP6363676B2/ja active Active
-
2017
- 2017-11-08 US US15/807,512 patent/US11136350B2/en active Active
-
2018
- 2018-02-01 JP JP2018016073A patent/JP6592120B2/ja active Active
- 2018-02-26 AU AU2018201371A patent/AU2018201371B2/en active Active
-
2019
- 2019-01-23 AR ARP190100147A patent/AR114228A2/es unknown
-
2020
- 2020-01-19 AU AU2020200373A patent/AU2020200373B2/en active Active
-
2021
- 2021-04-16 AR ARP210101010A patent/AR121861A2/es unknown
- 2021-09-13 US US17/473,910 patent/US20210403504A1/en active Pending
- 2021-12-16 AU AU2021286395A patent/AU2021286395B2/en active Active
-
2023
- 2023-12-19 US US18/545,528 patent/US20240117009A1/en active Pending
-
2024
- 2024-07-11 AU AU2024204779A patent/AU2024204779A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210403504A1 (en) | Method to produce an immunoglobulin preparation with improved yield | |
| US8796430B2 (en) | Method to produce an immunoglobulin preparation with improved yield | |
| AU2024204995A1 (en) | A method to produce an immunoglobulin preparation with improved yield | |
| HK1203838B (en) | Method for preparing an enriched igg composition from plasma | |
| HK1170168B (en) | Method for preparing an enriched igg composition from plasma | |
| HK1181682B (en) | Method for preparing an enriched igg composition from plasma | |
| HK1215931B (zh) | 从血浆制备富含igg的组合物的方法 |